Drug Response Profiling Services
KIYATEC offers cell-based Drug Response Profiling (DRP) services to help pharmaceutical and biotech companies accelerate the development of their small molecule compounds and biologic drugs. Our scientific team routinely performs advanced three-dimensional (3D) cell-based assays using immortalized cell lines, patient-derived xenograft (PDX) tissues or clinically sourced primary cancer tissues, including rare tumors, to better predict in vivo response. Our 3D tumor models are being used to identify in vitro drug response across a broad array of therapeutic classes and biological targets. Current funded programs and client projects include:
- 3D perfusion co-culture models for breast cancer, lung cancers (NSCLC and SCLC) and GBM
- 3D cell culture models for ovarian and pancreatic cancers
- 3D cell culture models for rare tumors
- Ex Vivo 3D PDX comparison studies
The KIYATEC Paradigm
We seek to maximize the clinical relevance of our preclinical services. KIYATEC personnel work closely with your scientific staff to understand your company’s drug development process, targets of interest and critical genotypic or phenotypic markers. We then customize a clinically relevant in vitro 3D microphysiologic model to your drug development needs. KIYATEC scientists are experts in the use and incorporation of multiple cell types to create highly organized in vivo-like microenvironments coupled with media perfusion. Since 2014, KIYATEC has focused significant efforts upon creating patient-matched immuno-oncology models comprised of human immune components (including tumor-associated macrophages (TAMs), T-Cells, cancer-associated fibroblasts (CAFs) and primary human tumors.
KIYATEC’s in vivo-like microenvironments closely mimic a patient’s tumor, liver, adipose tissue, stroma and vasculature. Accordingly, this type of 3D cell-based screening approach enables companies to better understand the phenotypic response of a particular tissue to both small molecule and biologic drugs. Whether you are investigating tumor-stromal interactions, drug resistance mechanisms, autocrine-paracrine-endocrine stimulation or ligand-receptor signaling, our scientists are experts at developing and testing physiologically relevant tissue microenvironments to assess drug response.
The key differentiator of KIYATEC is our ability to provide customers with highly relevant, predictive drug response profiles (DRPs) for both acute and chronic dosing strategies for the precise tissues and targets of interest in an in vitro assay platform. Our 3D perfusion culture technologies enable drug developers to identify critical changes in cellular morphology, functionality and phenotypic response in complex tissue-like microenvironments and 3D tumor models.